# N-Stearidonoylethanolamine Restores CA1 Synaptic Integrity and Reduces Astrocytic Reactivity After Mild Traumatic Brain Injury

**Authors:** Anastasia Egoraeva, Igor Manzhulo, Darya Ivashkevich, Anna Tyrtyshnaia

PMC · DOI: 10.3390/ijms27010471 · International Journal of Molecular Sciences · 2026-01-02

## TL;DR

This study shows that N-stearidonylethanolamine helps repair brain circuits and reduce inflammation after mild traumatic brain injury in mice.

## Contribution

The paper introduces SDEA as a novel ω-3 ethanolamide with multi-target therapeutic potential for mTBI.

## Key findings

- SDEA reduced astrocytic reactivity and restored synaptic integrity in the hippocampus.
- SDEA partially rescued cell proliferation in the dentate gyrus after mTBI.
- SDEA improved anxiety-like behavior and working memory in injured mice.

## Abstract

Mild traumatic brain injury (mTBI) disrupts hippocampal network function through coordinated alterations in glial reactivity, synaptic integrity, and adult neurogenesis. Effective therapeutic approaches targeting these interconnected processes remain limited. Lipid-derived molecules capable of modulating these mTBI-induced disturbances are emerging as promising neuroprotective candidates. Here, we investigated the effects of N-stearidonylethanolamine (SDEA), an ω-3 ethanolamide, in a mouse model of mTBI. SDEA treatment attenuated astrocytic reactivity, restored Arc expression, and improved dendritic spine density and morphology in the CA1 hippocampal area. In the dentate gyrus, mTBI reduced Ki-67-indexed proliferation while leaving DCX-positive immature neurons unchanged, and SDEA partially rescued proliferative activity. These effects were accompanied by improvements in anxiety-like behavior and working-memory performance. Together, these findings demonstrate that SDEA modulates several key components of the glia-synapse-neurogenesis axis and supports functional recovery of hippocampal circuits following mTBI. These results suggest that ω-3 ethanolamides may represent promising candidates for multi-target therapeutic strategies in mTBI.

## Linked entities

- **Genes:** ARC (activity regulated cytoskeleton associated protein) [NCBI Gene 23237], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345], DCX (doublecortin) [NCBI Gene 1641]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Dcx (doublecortin) [NCBI Gene 13193] {aka Dbct}
- **Diseases:** Traumatic Brain Injury (MESH:D000070642), mTBI (MESH:D001924), anxiety (MESH:D001007)
- **Chemicals:** Lipid (MESH:D008055), N-Stearidonoylethanolamine (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12786632/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12786632/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC12786632/full.md

---
Source: https://tomesphere.com/paper/PMC12786632